Novartis settles long-running patent dispute, resolving Daiichi Sankyo lawsuit for US$180 million
USA – Novartis has reached a settlement, paying US$180 million to Daiichi Sankyo’s Plexxikon...
Read More
Tag: Daiichi Sankyo
Merck invests heavily in expanding cancer drug portfolio with US$4 billion Daiichi Sankyo deal
USA — Merck, a pharmaceutical giant, has entered the realm of cancer drug research through a...
Read More
Daiichi Sankyo sets sights on independent development, building on Enhertu success
JAPAN — Daiichi Sankyo, a Japanese pharmaceutical company, is setting its sights on independent...
Read More
Japan’s MHLW approves Daiichi Sankyo’s Enhertu for breast cancer treatment
JAPAN — The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved Daiichi...
Read More
Seagen loses arbitration battle to Daiichi Sankyo over cancer medicine technology
USA – An arbitrator has ruled in Daiichi Sankyo’s favor in a legal battle against US Seagen over...
Read More
Takeda, Daiichi bet on long-term lifestyle data tracking to bolster drug discovery
JAPAN – Tohoku University’s Tohoku Medical Megabank Organization, pharmaceutical companies...
Read More
Seagen wins Enhertu patent case against Daiichi Sankyo
USA – A Texas federal jury determined that Daiichi Sankyo’s breast cancer blockbuster...
Read More
LATEST DIGITAL MAGAZINE
